Amphastar Pharmaceuticals (AMPH) EBT (2013 - 2026)

Amphastar Pharmaceuticals' EBT history runs 14 years deep, the most recent figure standing at $10.1 million for Q1 2026.

• In Q1 2026, EBT fell 67.43% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at -$26.1 million (down 114.67% YoY), while the FY2025 annual figure was -$5.3 million, down 102.73% from the prior year.
• EBT was $10.1 million for Q1 2026 at Amphastar Pharmaceuticals, up from -$97.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $63.6 million in Q3 2023 to a low of -$97.0 million in Q4 2025.
• Historically, EBT has averaged $28.7 million across 5 years, with a median of $33.6 million in 2023.
• The sharpest annual moves came in 2022 and 2025: EBT soared 467.72% in 2022, then tumbled 296.53% in 2025.
• A 5-year view of EBT shows it stood at $41.3 million in 2022, then advanced by 0.21% to $41.3 million in 2023, then increased by 19.42% to $49.4 million in 2024, then sank by 296.53% to -$97.0 million in 2025, then jumped by 110.36% to $10.1 million in 2026.
• The last three EBT figures came in at $10.1 million (Q1 2026), -$97.0 million (Q4 2025), and $21.5 million (Q3 2025), per Business Quant data.